Zhang, Li

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 357

The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy

Wang, G.-Z., Zhang, L., Zhao, X.-C., Gao, S.-H., Qu, L.-W., Yu, H., Fang, W.-F., Zhou, Y.-C., Liang, F., Zhang, C., et al. (2019) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 213

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Zhang, X., Zhou, Y., Chen, C., Fang, W., Cai, X., Zhang, X., Zhao, M., Zhang, B., Jiang, W., Lin, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer

Hepatitis B Virus StudiesCancer Immunotherapy and Biomarkers

Cited by 185

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma

Huang, P.-Y., Guo, S.-S., Zhang, Y., Lu, J.-B., Chen, Q.-Y., Tang, L.-Q., Zhang, L., Liu, L.-T., Zhang, L., & Mai, H.-Q. (2016) · Oncotarget

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 96

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019

Liu, J., Zhou, H., Zhang, Y., Fang, W., Yang, Y., Huang, Y., & Zhang, L. (2020) · Diabetes Care

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 55